2,3-Butanedione monoxime (BDM) as a myosin inhibitor
- 1 January 2002
- journal article
- Published by Springer Nature in Journal of Muscle Research and Cell Motility
- Vol. 23 (4) , 305-308
- https://doi.org/10.1023/a:1022047102064
Abstract
2,3-Butanedione monoxime (BDM) is the well-characterized, low-affinity, non-competitive inhibitor of skeletal muscle myosin-II. It has been widely used at millimolar concentrations in cell biological...Keywords
This publication has 21 references indexed in Scilit:
- The Kinetic Mechanism of Myo1e (Human Myosin-IC)Journal of Biological Chemistry, 2002
- A small-molecule inhibitor of skeletal muscle myosin IINature Cell Biology, 2001
- Kinetic Mechanism and Regulation of Myosin VIJournal of Biological Chemistry, 2001
- Modulation of Actin Affinity and Actomyosin Adenosine Triphosphatase by Charge Changes in the Myosin Motor DomainBiochemistry, 1998
- Butanedione Monoxime Promotes Voltage-dependent Inactivation ofL-Type Calcium Channels in Heart. Effects on Gating CurrentsJournal of Molecular and Cellular Cardiology, 1997
- Myosin is involved in postmitotic cell spreading.The Journal of cell biology, 1995
- Multiple Effects of 2,3‐Butanedione MonoximeBasic & Clinical Pharmacology & Toxicology, 1994
- Effect of 2,3-butanedione monoxime on myosin and myofibrillar ATPases. An example of an uncompetitive inhibitorBiochemistry, 1992
- Intermediate states of subfragment 1 and actosubfragment 1 ATPase: reevaluation of the mechanismBiochemistry, 1978
- A powerful reactivator of alkylphosphate-inhibited acetylcholinesteraseBiochimica et Biophysica Acta, 1955